A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

NCT05860036 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: anti-BCMA CAR-T
DRUG: VRd

Sponsor

Institute of Hematology & Blood Diseases Hospital, China